In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains

Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria

“…4 h owing to its high plasma protein binding [5] and stability against human renal dehydropeptidase. This antimicrobial agent appears to respond to a medical need owing to its pharmacokinetics, which is superior to that of imipenem and meropenem, its effectiveness against a wide range of Gram-negative and Gram-positive aerobic and anaerobic bacteria [6][7][8][9][10][11][12][13][14][15] and its potential as an outpatient parenteral antimicrobial therapy [16]. Although ertapenem shows limited activity against Enterococcus spp., Pseudomonas aeruginosa and other non-fermentative Gramnegative bacteria associated with nosocomial infections, this new carbapenem is, however, promising for the treatment of a variety of community-acquired infections [17][18][19][20][21][22][23][24][25][26] The 337 obligate anaerobic bacterial strains were isolated from human clinical specimens from October 2002 to March 2003 and were identified according to classical methods [36].…”